Shares

40 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.88 - $4.89 $4,815 - $8,176
-1,672 Reduced 50.0%
1,672 $5,000
Q2 2023

Aug 10, 2023

BUY
$4.45 - $7.57 $14,880 - $25,314
3,344 New
3,344 $18,000
Q2 2022

Aug 11, 2022

SELL
$1.92 - $6.28 $8,156 - $26,677
-4,248 Closed
0 $0
Q1 2022

Jun 20, 2023

BUY
$5.07 - $7.2 $21,537 - $30,585
4,248 New
4,248 $25,000
Q1 2022

Mar 30, 2023

SELL
$5.07 - $7.2 $63,633 - $90,367
-12,551 Reduced 74.71%
4,248 $25,000
Q1 2022

May 12, 2022

SELL
$5.07 - $7.2 $63,633 - $90,367
-12,551 Reduced 74.71%
4,248 $26,000
Q4 2021

Jun 21, 2023

BUY
$5.67 - $8.54 $95,250 - $143,463
16,799 New
16,799 $108,000
Q4 2021

Mar 30, 2023

SELL
$5.67 - $8.54 $12,491 - $18,813
-2,203 Reduced 11.59%
16,799 $108,000
Q4 2021

Feb 15, 2022

SELL
$5.67 - $8.54 $12,491 - $18,813
-2,203 Reduced 11.59%
16,799 $108,000
Q3 2021

Jun 21, 2023

BUY
$13.4 - $16.3 $254,626 - $309,732
19,002 New
19,002 $262,000
Q2 2021

Jun 21, 2023

BUY
$14.81 - $19.13 $281,419 - $363,508
19,002 New
19,002 $281,000
Q2 2021

Mar 30, 2023

BUY
$14.81 - $19.13 $11,314 - $14,615
764 Added 4.19%
19,002 $281,000
Q2 2021

Aug 16, 2021

BUY
$14.81 - $19.13 $281,153 - $363,163
18,984 Added 105466.67%
19,002 $282,000
Q1 2021

Jun 26, 2023

BUY
$14.52 - $23.53 $264,815 - $429,140
18,238 New
18,238 $325 Million
Q1 2021

May 14, 2021

SELL
$14.52 - $23.53 $264,554 - $428,716
-18,220 Reduced 99.9%
18 $325,000
Q4 2020

Jun 22, 2023

BUY
$10.14 - $15.19 $184,933 - $277,035
18,238 New
18,238 $260,000
Q3 2020

Jun 26, 2023

BUY
$9.57 - $21.32 $174,537 - $388,834
18,238 New
18,238 $184,000
Q2 2020

Jun 26, 2023

BUY
$12.21 - $16.99 $222,685 - $309,863
18,238 New
18,238 $268,000
Q2 2020

Mar 30, 2023

BUY
$12.21 - $16.99 $36,544 - $50,851
2,993 Added 19.63%
18,238 $268,000
Q2 2020

Aug 14, 2020

BUY
$12.21 - $16.99 $36,544 - $50,851
2,993 Added 19.63%
18,238 $268,000
Q1 2020

Jul 12, 2023

BUY
$9.03 - $19.72 $137,662 - $300,631
15,245 New
15,245 $203,000
Q1 2020

Mar 30, 2023

BUY
$9.03 - $19.72 $9,662 - $21,100
1,070 Added 7.55%
15,245 $203,000
Q1 2020

May 15, 2020

BUY
$9.03 - $19.72 $9,662 - $21,100
1,070 Added 7.55%
15,245 $204,000
Q4 2019

Jul 12, 2023

BUY
$13.01 - $17.15 $184,416 - $243,101
14,175 New
14,175 $199,000
Q4 2019

Mar 30, 2023

SELL
$13.01 - $17.15 $12,814 - $16,892
-985 Reduced 6.5%
14,175 $199,000
Q4 2019

Feb 14, 2020

SELL
$13.01 - $17.15 $12,814 - $16,892
-985 Reduced 6.5%
14,175 $200,000
Q3 2019

Jul 12, 2023

BUY
$14.55 - $20.56 $220,578 - $311,689
15,160 New
15,160 $247,000
Q3 2019

Mar 30, 2023

SELL
$14.55 - $20.56 $12,280 - $17,352
-844 Reduced 5.27%
15,160 $247,000
Q3 2019

Nov 14, 2019

SELL
$14.55 - $20.56 $12,280 - $17,352
-844 Reduced 5.27%
15,160 $248,000
Q2 2019

Jul 12, 2023

BUY
$15.0 - $19.62 $240,060 - $313,998
16,004 New
16,004 $251,000
Q1 2019

Jul 13, 2023

BUY
$11.65 - $17.72 $186,446 - $283,590
16,004 New
16,004 $277,000
Q1 2019

Mar 30, 2023

BUY
$11.65 - $17.72 $186,446 - $283,590
16,004 New
16,004 $277,000
Q1 2019

May 16, 2019

BUY
$11.65 - $17.72 $79,872 - $121,488
6,856 Added 74.95%
16,004 $277,000
Q1 2019

May 15, 2019

SELL
$11.65 - $17.72 $79,872 - $121,488
-6,856 Reduced 42.84%
9,148 $965,000
Q4 2018

Jul 13, 2023

BUY
$10.72 - $16.73 $171,562 - $267,746
16,004 New
16,004 $178,000
Q4 2018

Feb 14, 2019

BUY
$10.72 - $16.73 $138,405 - $216,001
12,911 Added 417.43%
16,004 $178,000
Q3 2018

Jul 13, 2023

BUY
$17.73 - $26.69 $263,361 - $396,453
14,854 New
14,854 $363 Million
Q3 2018

Nov 14, 2018

SELL
$17.73 - $26.69 $208,522 - $313,901
-11,761 Reduced 79.18%
3,093 $76,000
Q4 2017

Feb 15, 2018

SELL
$13.26 - $22.86 $173,626 - $299,328
-13,094 Reduced 46.85%
14,854 $289,000
Q2 2017

Aug 14, 2017

BUY
N/A
27,948
27,948 $556,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $762M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.